Crispr Therapeutics AG (CRSP)

62.12
-3.23(-4.94%)
  • Volume:
    550,771
  • Day's Range:
    61.74 - 66.31
  • 52 wk Range:
    42.51 - 110.01

CRSP Overview

Prev. Close
65.35
Day's Range
61.74-66.31
Revenue
915.36M
Open
66.02
52 wk Range
42.51-110.01
EPS
-8.24
Volume
550,771
Market Cap
4.82B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,401,785
P/E Ratio
-
Beta
1.92
1-Year Change
-41.28%
Shares Outstanding
78,009,260
Next Earnings Date
Nov 02, 2022
What is your sentiment on Crispr Therapeutics?
or
Vote to see community's results!

Crispr Therapeutics AG News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Crispr Therapeutics AG Analysis

Crispr Therapeutics AG Company Profile

Crispr Therapeutics AG Company Profile

Employees
473

CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.

Read More

Analyst Price Target

Average115.30 (+86.09% Upside)
High220
Low50
Price61.96
No. of Analysts27
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • Time to load up
    0
    • Nice price
      0
      • The earning date posted here is wrong. Its 2/16/22. So miss leading
        0
        • wow... it's bucking the trend
          0
          • another cathy wood investment ¡ Good luck ...enjoy the elevator
            4
            • CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignanciesZUG, Switzerland and CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) http://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-announces-fda-regenerative-medicine-advanced
              0
              • Amazing how fast this went from breakthrough life changing technology to garbage in about a month
                1
                • One paragraph of good news and this goes back to 160 in a day after the sheep pile in. Not just this ticker but any of them.
                  0
                  • Added 1100 shares
                    2
                    • now u must be regretting
                      0
                    • nope I'm long!
                      0
                  • keep tanking this stock what a hopeless
                    6